KEY POINTS
- Fifteen patients with intermediate-risk prostate cancer received 35 Gy in five fractions on a 1.5-T Elekta Unity MRI-linac. R2* mapping was performed at simulation and before fractions 1, 3, and 5; seven patients had received androgen deprivation therapy, and six underwent additional imaging approximately three months after treatment.
- Whole-prostate R2* measurements showed good short-term repeatability, with a within-subject coefficient of variation of 4.4%. Repeatability was substantially poorer for dominant intraprostatic lesion R2*, at 22.6%, reflecting greater contouring, registration, and susceptibility-related uncertainty.
- After two SABR fractions, whole-prostate R2* decreased by 1.77 s⁻¹, corresponding to approximately 11.1% from baseline (p=0.003). At the same time, prostate volume increased by 8.05 cm³, or approximately 22.1% (p=0.001), consistent with acute treatment-associated swelling.
- Similar R2* changes were observed in the dominant intraprostatic lesion. Among the 11 evaluable patients, tumour R2* decreased by 3.11 s⁻¹, approximately 14.6%, after two fractions (p=0.003), while dominant-lesion volume did not change significantly.
- By fraction 5, whole-prostate R2* remained approximately 11.1% below baseline, while prostate volume remained approximately 17.1% higher. In the six-patient follow-up subset, however, neither whole-prostate R2* nor volume was significantly different from pretreatment baseline at a mean of 81 days after therapy.
- ADT had a major effect on baseline imaging phenotype: patients receiving ADT had higher baseline R2* (p=0.006) and smaller prostate volume (p=0.003). However, ADT did not significantly modify the treatment-induced trajectory (p=0.51).
- Whole-prostate and tumour R2* were not significantly different either before treatment or after two fractions, and treatment-induced R2* and volume changes were not significantly correlated. Together with bowel-gas susceptibility artefacts and poor lesion-level repeatability, this limits interpretation of R2* as a tumour-specific hypoxia biomarker at present.
CLINICAL TAKEAWAY
Longitudinal R2* mapping can be integrated into five-fraction MRI-linac prostate SABR and can detect acute biological or physiological changes during treatment. The measured signal is not yet sufficiently tumour-specific or mechanistically validated to guide dose adaptation, but it provides a platform for future biologically guided MRI-linac studies.